Phospholipase A2 levels in acute chest syndrome of sickle cell disease

Blood

Volumn 87, Issue 6, 1996, Pages 2573-2578

  Styles, Lori A ^a   Schalkwijk, Casper G ^b   Aarsman, Anton J ^b   Vichinsky, Elliott P ^b   Lubin, Bertram H ^b   Kuypers, Frans A ^b  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN; PHOSPHOLIPASE A2; FATTY ACID; PHOSPHOLIPASE A;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FAT EMBOLISM; HOSPITALIZATION; HUMAN; HYPOXIA; LUNG ALVEOLUS OXYGEN TENSION; LUNG DISEASE; LUNG EMBOLISM; PNEUMONIA; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SYNDROME; ACUTE DISEASE; BLOOD; COMPARATIVE STUDY; ENZYMOLOGY; FEMALE; INFANT; INFLAMMATION; ISCHEMIA; MALE; METABOLISM; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ACUTE DISEASE; ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; EMBOLISM, FAT; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; INFANT; INFLAMMATION; ISCHEMIA; LUNG DISEASES; MALE; PHOSPHOLIPASES A; PNEUMONIA; PULMONARY EMBOLISM;

EID: 0029665150     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.6.2573.bloodjournal8762573     Document Type: Article

References (64)

1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O. Steinberg MH, Klug PP: Mortality in sickle cell disease: Life expectancy and risk factors for early death. N Engl J Med 330:1639, 1994
2. Vichinsky EP. Comprehensive care in sickle cell disease: Its impact on morbidity and mortality. Semin Hematol 28:220, 1991
3. Sprinkle RH, Cole T, Smith S, Buchanan GR: Acute chest syndrome in children with sickle cell disease: A retrospective analysis of 100 hospitalized cases. Am J Pediatr Hematol Oncol 8:105. 1986
4. Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C: Sickle cell chronic lung disease: Prior morbidity and the risk of pulmonary failure. Medicine 67:66, 1988
5. DeCeulaer K, McMullen KW, Maude GH, Keatinge R, Serjeant G: Pneumonia in young children with homozygous sickle cell disease: Risk and clinical features. Eur J Pediatr 144:255, 1985
6. Weil JV, Castro O, Malik AB, Rodgers G, Bonds DR, Jacobs TP: NHLBI Workshop summary: Pathogenesis of lung disease in sickle hemoglobinopathies. Am Rev Respir Dis 148:149, 1993
7. Poncz M, Kane E, Gill FM. Acute chest syndrome in sickle cell disease: Etiology and clinical correlates. J Pediatr 107:861, 1985
8. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS, and The Coopertive Study of Sickle Cell Disease: The acute chest syndrome in sickle cell disease: Incidence and risk factors. Blood 84:643, 1994
9. Charache S, Scott JC, Charache P: "Acute chest syndrome" in adults with sickle cell anemia. Arch Intern Med 139.67, 1979
10. Vichinsky E, Williams R, Das M, Earles AN, Lewis N, Adler A, Mcquitty J: Pulmonary fat embolism: A distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 83:3107, 1994
11. Shapiro MP, Hayes JA: Fat embolism in sickle cell disease. Arch Intern Med 144:181, 1984
12. Oppenheimer EH, Esterly JR: Pulmonary changes in sickle cell disease. Am Rev Respir Dis 103:858, 1971
13. Levy D: The fat embolism syndrome, a review. Clin Orthop 261:281, 1990
14. Moylan JA, Birmbaum M, Katz A, Everson MA: Fat emboli syndrome. J Trauma 16:341, 1976
15. Peltier LF: The diagnosis and treatment of fat embolism. J Trauma 11:661, 1971
16. McCarthy B, Mammen E, LeBlanc LP, Wilson RF: Subclinical fat embolism: A prospective study of 50 patients with extremity fractures. J Trauma 13:9, 1973
17. Fabian TC, Hoots AV, Stanford DS, Patterson CR, Mangiante EC. Fat embolism syndrome: Prospective evaluation in 92 fracture patients. Crit Care Med 18:42, 1990
18. Schuster DP: ARDS: Clinical lessons from the oleic acid model of acute lung injury. Am J Respir Crit Care Med 149-245, 1994
19. Henderson WR: Eicosanoids and platelet-activating factor in allergic respiratory diseases. Am Rev Respir Dis 143 S86, 1991
20. Lewis RA, Austen KF, Soberman RJ: Leukotrienes and other products of the 5-lipoxygenase pathway: Biochemistry and relation to pathobiology in human disease. N Engl J Med 323:645, 1990
21. Henderson WR: Eicosanoids and lung inflammation. Am Rev Respir Dis 135:1176, 1987
22. Henderson WR Jr: Lipid-derived and other chemical mediators of inflammation in the lung. Allergy Clin Immunol 79.543, 1987
23. 2, in Brown BL, Dobson RM (eds): Advances in Second Messenger and Phosphoprotein Research, vol 28. New York, NY, Raven, 1993, p 81
24. 2 in inflammatory diseases. Clin Chem 39:2453, 1993
25. 2 in rat cultured astrocytes: Two distinct pathways of the gene expression. Biol Chem 266:9956, 1991
26. 2 - a mediator between proximal and distal effectors of inflammation. Immunol Today 12:143, 1991
27. 2. Biol Chem 269:13057, 1994
28. Baur M, Schmid T-O, Landauer B: Role of phospholipase A in multiorgan failure with special reference to ARDS and acute renal failure. Klin Wochenschr 67:196, 1989
29. 2 propeptide in acute lung injury. Lancet 344:1472, 1994
30. 2 levels: Correlation with the hemodynamic and pulmonary changes in gram-negative septic shock J Lab Clin Med 104:873, 1984
31. 1 activity from beef pancreas. Biochim Biophys Acta 348:197, 1974
32. Van den Bosch H, Aarsman AJ: A review on methods of phospholipase A determination. Agents Actions 9:382, 1979
33. 2 in arthritis plasma using a newly developed sandwich ELISA. Br J Rheumatol 31:175, 1992
34. 2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem 266:2647, 1991
35. 2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis. Inflammation 15:355, 1991
36. 2 in the pathogenesis of the hemodynamic changes in endotoxin shock. Can J Physiol Pharmacol 61:561, 1983
37. 2 levels with circulatory collapse. Crit Care Med 16:1, 1988
38. 2: Potential mediators of the systemic inflammatory response syndrome and the multiple organ dysfunction syndrome. Crit Care Med 21:957, 1993
39. 2 with multiple system organ dysfunction due to salicylate intoxication Crit Care Med 21:1087, 1993
40. 2 in the physiopathology of osteoarthritis. J Rheumalol 18:117, 1991
41. 2-activating protein in endothelial cells. Biochem J 250:125, 1988
42. 2 expression in adults with malaria. Infect Immun 60:3928, 1992
43. 2 release from rat renal mesangial cells. Biochem Biophys Res Commun 159:385, 1989
44. 2. J Appl Physiol 66:261, 1989
45. 2: Structural and functional changes. Am Rev Respir Dis 143:1102, 1991
46. Tighe D, Moss R, Parker-Williams J: A phospholipase inhibitor modifies the pulmonary damage associated with peritonitis in rabbits. Intensive Care Med 13:284, 1987
47. 2 inhibition decouples lung injury from gut ischemia-reperfusion. Surgery 112:173, 1992
48. 2 and pulmonary changes in acute fulminant pancreatitis. Resuscitation 10:79, 1982
49. 2 in patients with multiple injuries. J Trauma 30.1285, 1990
50. Emre U, Milier ST, Rao SP, Rao M: Alveolar-arterial oxygen gradient in acute chest syndrome of sickle cell disease. J Pediatr 123:272, 1993
51. Hassell KL, Deutsch JC, Kolhouse JF, O'Connell JL, Weil JV, Lane PA: Elevated serum levels of free fatty acids in sickle cell patients with acute chest syndrome and acute multi-organ failure syndrome. Blood 84:412A, 1994
52. 2 in septic shock. Agents Actions 19:194, 1986
53. 2 and Its Regulatory Factors. New York, NY: Plenum Press, 1990, p 49
54. 2. New York, NY, Plenum, 1990, p 1
55. 2 and anti-oxidant activity. Prostaglandins Leukotrienes Essent Fatty Acids 43:63, 1991
56. 2. New York, NY, Plenum, 1990, p 169
57. 2 activity: Implications for inflammatory diseases. DNA Cell Biol 11:233, 1992
58. Thomson APJ, Dick M: Endotoxinaemia in sickle cell disease. Clin Lab Haematol 10:397, 1988
59. Francis RB Jr, Haywood LJ: Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. Natl Med Assoc 84:611, 1992
60. 2 agonist U46619. Arteriosclerosis Thromb 13:421, 1993
61. Ibe BO, Kurantsin-Mills J, Raj JU, Lessin LS: Plasma and urinary leukotrienes in sickle cell disease: Possible role in the inflammatory process. Eur J Clin Invest 24:57, 1994
62. Kurantsin-Mills J, Ibe BO, Natta CL, Raj JU, Siegel RS, Lessin LS: Elevated urinary levels of thromboxane and prostacyclin metabolites in sickle cell disease reflects activated platelets in the circulation. Br J Haematol 87:580, 1994
63. Buchanan GR, Holtkamp CA: Plasma levels of platelet and vascular prostaglandin derivatives in children with sickle cell anaemia. Thromb Haemost 54:394, 1985
64. Mankad VN, Williams JP, Harpen M, Longenecker G, Brogdon B, Moore B: Magnetic resonance imaging, percentage of dense cells and serum prostanoids as tools for objective assessment of pain crisis: A preliminary report, in Pathophysiological Aspects of Sickle Cell Vaso-Occlusion. New York, NY, Liss, 1987, p 337